Outcome

Hyperbaric oxygen therapy (HBO) at 2.4 atmospheres absolute (ATA) with 100% oxygen administered once daily for five days significantly reduced latency time (LT) and improved the aggregation index in high-risk diabetic patients with non-insulin dependent diabetes mellitus (NIDDM).

Introduction

Hyperglycemia or elevated blood sugar levels in non-insulin dependent diabetes mellitus (NIDDM) can lead to complications such as platelet aggregation and increased blood viscosity often resulting in clotting problems. This study investigates the potential benefits of hyperbaric oxygen therapy (HBO) for high-risk diabetic patients in managing these complications. HBO involves breathing 100% oxygen at pressures higher than normal atmospheric levels. Participants were divided into two groups: one receiving HBO at 2.4 atmospheres absolute (ATA) and a control group receiving normobaric oxygen therapy (NONB) at 1 ATA with 20% oxygen. Both groups underwent their respective treatments once daily for five days.

The study measured various platelet aggregation parameters—latency time (LT) aggregation speed aggregation index and aggregation percentage—both before and after the treatment sessions. The results demonstrated that the HBO group experienced significant improvements in LT and aggregation index though changes in aggregation speed and aggregation percentage were less pronounced. Conversely the NONB control group showed notable improvements in aggregation speed and index but did not achieve significant changes in LT and aggregation percentage.

These findings suggest that HBO might be a promising therapy to reduce certain blood clotting risks in diabetic patients by improving aspects of platelet function. Overall this research provides valuable insights into how hyperbaric oxygen therapy could potentially benefit individuals with NIDDM helping manage platelet aggregation and possibly reducing the risk of clot-related complications.

Results

The study evaluated the impact of hyperbaric oxygen (HBO) therapy on platelet aggregation in patients with non-insulin dependent diabetes mellitus (NIDDM). Participants were divided into two groups: the HBO group received 2.4 atmospheres absolute (ATA) of 100% oxygen while the control group (NONB) received 1 ATA of 20% oxygen. Both groups underwent their respective treatments daily for five days.

In the HBO group significant reductions were observed in latency time (LT) and aggregation index following treatment. These improvements suggest that HBO therapy may enhance platelet function by reducing the time required for platelets to begin aggregating and decreasing the overall tendency for platelets to clump together. However changes in aggregation speed and aggregation percentage in the HBO group were not statistically significant.

Conversely the NONB control group exhibited notable improvements in aggregation speed and aggregation index indicating that even normobaric oxygen therapy at 1 ATA can beneficially affect some platelet aggregation parameters. However no significant changes were observed in LT and aggregation percentage for the control group.

These findings collectively indicate that HBO therapy at 2.4 ATA with 100% oxygen can positively influence specific platelet aggregation parameters particularly latency time and aggregation index in patients with NIDDM. While the NONB treatment also led to significant reductions in aggregation speed and aggregation index the distinct benefits observed with HBO therapy highlight its potential as a targeted treatment to reduce the risks of clot-related complications in diabetic patients by improving platelet function.

Conclusion

In conclusion this study showcases the potential efficacy of hyperbaric oxygen therapy (HBO) in managing platelet aggregation complications in high-risk diabetic patients with non-insulin dependent diabetes mellitus (NIDDM). The significant reduction in latency time (LT) and improvement in the aggregation index observed in the HBO group suggest that a daily regimen of HBO at 2.4 ATA with 100% oxygen for five days can beneficially influence platelet function. These findings imply that HBO could be an effective adjunctive treatment to address platelet-related complications and improve blood rheology in diabetic patients. Future research should focus on optimizing HBO protocols and exploring the long-term impacts of such therapy on broader diabetic complications to validate and expand upon these promising results.